Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 7Genitourinary 3Head & Neck 2Gynecologic 2Breast 2Thoracic 1Dermatologic 1

Conditions

Nasopharyngeal Carcinoma 11Head and Neck Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Carcinoma, Non-Small-Cell Lung 8Melanoma 5Neoplasm Metastasis 4Carcinoma, Renal Cell 4Triple Negative Breast Neoplasms 3Recurrence 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Esophageal Squamous Cell Carcinoma 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Urinary Bladder Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Prostatic Neoplasms 1Oropharyngeal Neoplasms 1Nasopharyngeal Cancinoma (NPC) 1Mouth Neoplasms 1Mesothelioma, Malignant 1Lung Neoplasms 1Kidney Neoplasms 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Squamous Cell 1Carcinoma, Merkel Cell 1

Interventions

pembrolizumab 23Nivolumab 10Trastuzumab 7Gemcitabine 6Cisplatin 6Cetuximab 6Docetaxel 5spartalizumab 4atezolizumab 4Ipilimumab 4Drug Therapy 4Cyclophosphamide 4Carboplatin 4Capecitabine 4palbociclib 3fludarabine 3cemiplimab 3Radiotherapy 3Magnetic Resonance Spectroscopy 3Erlotinib Hydrochloride 3Bortezomib 3ulixertinib 2trametinib 2sargramostim 2pertuzumab 2avelumab 2amminedichloro(2-methylpyridine)platinum(II) 2aldesleukin 2Taxes 2TH 302 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × Immune Checkpoint Inhibitors × Head & Neck × Clear all
NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Maastricht University Medical Center

Phase 1/2 Recruiting
126 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT05704985 2025-05-29

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

DEKA Biosciences

Phase 1 Active not recruiting
39 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Kidney Neoplasms, Neoplasms, Pancreatic Neoplasms, Skin Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡